Drugs / Yallaferon®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01824992 | Mar 2011 → Mar 2012 | human papilloma virus infection | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT02801383 Comparator | Sep 2015 → Mar 2017 | human papilloma virus infection | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2006-10-18 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗
Yallaferon® ("Recombinant Human Interferon α-2b gel") has been approved for an additional indication for use in the treatment of cervicitis by the SFDA of China. |
| 2005-09-07 | Lee's Pharmaceutical Limited | Regulatory New Indication Approved for Yallaferon® leespharm.com ↗
Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) announced today that Yallaferon® (Recombinant Human Interferon α-2b gel) has been approved for an additional indication for use in the treatment of herpes zoster by the SFDA of China. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-01-01 | Lee's Pharmaceutical Limited | Listing on Guidance for Family Choice Pharmacy of Lee’s Pharm signature products — Ferplex® and Yallaferon® leespharm.com ↗ |
| 2021-12-29 | Lee's Pharmaceutical Limited | Lee’s Pharm in-house product Yallaferon® was honoured with “2021 Biopharmaceutical Excellent Brand” Award leespharm.com ↗ |
| 2006-10-18 | Lee's Pharmaceutical Limited | New Indication Approved for Cervicitis for Yallaferon leespharm.com ↗ |
| 2005-12-20 | Lee's Pharmaceutical Limited | Completion of the Study of Yallaferon® in Cervicitis Patients leespharm.com ↗ |
| 2005-09-07 | Lee's Pharmaceutical Limited | New Indication Approved for Yallaferon® leespharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yallaferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02801383 ↗ |
| Known as | recombinant human interferon α-2b | “recombinant human interferon α-2b gel (Yallaferon®)” NCT02801383 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interferon α-2b gel (Yallaferon®)” NCT01824992 ↗ |